Glaukos’ Net Sales Increase 55 Percent in Q1-2017

May 12, 2017: By Jon Swedien

GlaukosGlaukos’ net sales totaled $35.9 million in Q1-2017, an increase of 55 percent over Q1-2016, the San Clemente, California, company announced May 3.

Glaukos raised its 2017 net sales guidance to a range of $162 million to $167 million from $160 million to $165 million. The new guidance represents a 42 percent to 46 percent increase over the company’s 2016 net sales of $114.4 million. Glaukos’ net sales were $71.7 million in 2015.

“We are off to a solid start in 2017, focusing our resources and energy on driving US adoption of our flagship iStent Trabecular Micro-Bypass Stent, pursuing regulatory approval of our pipeline technologies, and expanding our direct sales operations into targeted international markets,” said Thomas Burns, Glaukos president and CEO.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023